optimer pharmaceuticals inc
(OPTR:NASDAQ GS)
Earnings & Estimates Summary - OPTIMER PHARMACEUTICALS INC (OPTR)
2012 revenues at Optimer Pharmaceuticals, Inc. totaled $101.5M USD, while annual losses equaled $1.91 per share.
Quarterly Earnings & Estimates - OPTIMER PHARMACEUTICALS INC (OPTR)
85.71%
Optimer Pharmaceuticals, Inc.'s Quarterly Earnings
Optimer Pharmaceuticals, Inc. reported 1st quarter 2013 losses of $0.65 per share on 05/11/2013.
Annual Earnings & Estimates - OPTIMER PHARMACEUTICALS INC (OPTR)
Optimer Pharmaceuticals, Inc.'s Annual Earnings
Optimer Pharmaceuticals, Inc. reported annual 2012 losses of $1.91 per share on 03/2/2013.
Quarterly Revenues - OPTIMER PHARMACEUTICALS INC (OPTR)
Optimer Pharmaceuticals, Inc.'s Quarterly Revenues
Optimer Pharmaceuticals, Inc. had 1st quarter 2013 revenues of $19.4M USD. This missed the $21.3M USD consensus estimate of the 9 analysts following the company. This was 35.1% above the prior year's 1st quarter results.
Annual Revenues - OPTIMER PHARMACEUTICALS INC (OPTR)
Optimer Pharmaceuticals, Inc.'s Annual Revenues
Optimer Pharmaceuticals, Inc. had revenues for the full year 2012 of $101.5M USD. This was -30.0% below the prior year's results.
| Recently Viewed | |||
| OPTR:US | $14.70 USD | -0.27 |  |
| Company | Last | Change |
| Enzon Pharmaceuticals Inc | $3.13 USD | -0.04 |
| Orexigen Therapeutics Inc | $6.02 USD | -0.02 |
| Pfizer Inc | $28.70 USD | -0.26 |
| Synta Pharmaceuticals Corp | $7.43 USD | -0.07 |
| ViroPharma Inc | $25.30 USD | -0.58 |
| View Industry Companies | ||
Industry Analysis
OPTR
Industry Average
| Valuation | OPTR | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 6.7x |
|
| Price/Book | 6.8x |
|
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | 6.0x |
|
Post a JobJobs
- New York, NY |Posted: May 17
- San Francisco, CA | YelpPosted: May 02
- San Francisco, CA | YelpPosted: May 02
- Thornton, CO | IntuitPosted: May 20
Sponsored Financial Commentaries
Sponsored Links
To contact OPTIMER PHARMACEUTICALS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.
Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.
